フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
LILLY (ELI) & COMPANY - Additional Phase III Clinical Trials LILLY (ELI) & COMPANY - Additional Phase III Clinical Trials PR...
LILLY (ELI) & COMPANY - 2012 Financial Guidance;2013 Financial Guidance LILLY (ELI) & COMPANY - 2012 Financial Guidance;2013 Financial...
LILLY (ELI) & COMPANY - SEC Settlement Press Release LILLY (ELI) & COMPANY - SEC Settlement Press Release PR Newswire London, December...
LILLY (ELI) & COMPANY - LLY Sets Dates for Financial Guidance & Q4 2012 Results LILLY (ELI) & COMPANY - LLY Sets Dates for...
LILLY (ELI) & COMPANY - Tabalumab RA Study BCDM Discontinuation LILLY (ELI) & COMPANY - Tabalumab RA Study BCDM Discontinuation PR...
LILLY (ELI) & COMPANY - Next Steps for Solanezumab LILLY (ELI) & COMPANY - Next Steps for Solanezumab PR Newswire London, December 12...
LILLY (ELI) & COMPANY - Cardiovascular outcome study on Tradjenta® (linagliptin) LILLY (ELI) & COMPANY - Cardiovascular outcome study...
LILLY (ELI) & COMPANY - EC approves Cialis - benign prostatic hyperplasia LILLY (ELI) & COMPANY - EC approves Cialis - benign prostatic...
LILLY (ELI) & COMPANY - 3rd Quarter Results LILLY (ELI) & COMPANY - 3rd Quarter Results PR Newswire London, October 25 Eli Lilly and...
LILLY (ELI) & COMPANY - Dula Topline Release LILLY (ELI) & COMPANY - Dula Topline Release PR Newswire London, October 22 Date: October...
LILLY (ELI) & COMPANY - Amyvid Recommended for Approval in EU LILLY (ELI) & COMPANY - Amyvid Recommended for Approval in EU PR...
LILLY (ELI) & COMPANY - FDA Approves New Use of ALIMTA LILLY (ELI) & COMPANY - FDA Approves New Use of ALIMTA PR Newswire London...
LILLY (ELI) & COMPANY - Lilly Declares Q4 2012 Dividend LILLY (ELI) & COMPANY - Lilly Declares Q4 2012 Dividend PR Newswire London...
LILLY (ELI) & COMPANY - Mechanistic Differences Between FORTEO & Zoledronic Acid LILLY (ELI) & COMPANY - Mechanistic Differences...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約